Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

Eli Lilly announced positive Phase 3 trial data for retatrutide, its next-generation obesity drug targeting three metabolic pathways, with weight loss ranging from 20.8% to 22.6% across patient cohorts; the company plans to submit an FDA biologics application in Q1 2027.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.